Shane Schaffer

About Shane Schaffer

Shane J. Schaffer is the Co-founder, Chairman, and Chief Executive Officer of Cingulate Therapeutics, a Phase 3 clinical-stage biopharmaceutical company headquartered in Kansas City, Kansas. The company focuses on developing several branded, next-generation pharmaceutical products, notably for Attention Deficit/Hyperactivity Disorder (ADHD), anxiety disorders, and insomnia.

Boasting a robust 25-year career in the pharmaceutical industry, he is a seasoned expert in drug development and commercialization. His strategic leadership and entrepreneurial flair have been instrumental in various business aspects, including product launches, brand planning, joint venture brand management, life cycle management, and market development, cementing his reputation in the biopharmaceutical and marketing arenas.

He obtained his doctoral degree in Pharmacy from the University of Kansas in 1999, followed by a post-doctoral pharmaceutical industry fellowship at Rutgers University’s College of Pharmacy. During his fellowship, he worked at Pfizer Worldwide Marketing and a facility in Morris Plains.

While at Pfizer Worldwide Marketing in New York, NY, he undertook the role of Marketing Manager. There, he collaboratively developed pre-launch strategies and spearheaded the Global Communications Intranet, fostering effective communications between medical and marketing teams. He also helped establish and implement the Pfizer Medical and Academic Partnership in Pain Management.